9th Annual Biomarkers Congress

View Profile

Pre/Non Reviewed Papers, Proceedings

Year Title Authors
1. 2010 Two Kinetic Phases of Distribution and Tumor Targeting by Adoptively Transferred T Cell Receptor Engineered Lymphocytes Inducing Robust Antitumor Responses.
2. 2010 Small interfering RNA knockdown of ribonucleotide reducatase inhibits melanoma cell line proliferation alone or synergistically with high dose temozolomide.
3. 2010 The impact of ex vivo clinical grade activation protocols on human T cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy
4. 2010 Reversal of Melanoma Resistance to Gemcitabine by Checkpoint Kinase Inhibition
5. 2010 Selective inhibition of BRAF-V600E activating mutations induce major regressions in patients with metastatic melanoma
6. 2010 Enhanced tumor control with adoptive transfer of TCR engineered T cells expressing TCL1
7. 2010 Overcoming barriers to programming a therapeutic cellular immune response to fight melanoma
8. 2010 CD40 Expression by Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting with the Therapeutic Anti-CD40 Antibody CP-870,893
9. 2010 Invariant HLA-E T cells, a prevalent human T cell population endogenously programmed for cytolysis, IL-22 production, and immune regulation
10. 2009 Completion of a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032: early efficacy signal confirmed in advanced melanoma.
11. 2009 Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer
12. 2009 PLX4032, a highly selective V600EBRAF kinase inhibitor: correlation of activity with pharmacokinetic and pharmacodynamic parameters in a Phase I trial
13. 2009 Manual of Clinical Oncology, Sixth edition
14. 2009 Vaccine Therapy in Patients with Renal Cell Carcinoma.
15. 2009 Alpha Interferon in the Post-Surgical Management of High Risk Melanoma: Is It Worth It?
16. 2009 Do we need different response assessment criteria for tumor immunotherapy?
17. 2009 Gernhardt. Safety and tolerability of 1-hour intravenous infusion of tremelimumab (CP-675,206) in patients with surgically incurable stage III or IV melanoma
18. 2009 Targeting Immunological Synapse. New Horizons in Immunotherapy for Cancer.
19. 2009 Analysis of Optimal Lentiviral Transduction Conditions, Immunophenotype and Functional Activity of Human Primary T Cells Engineered To Simultaneously Express a Mart-1 T Cell Receptor and a PET Reporter for Anti-Melanoma Therapy
20. 2009 Genetic Engineering of a Cancer-targeted Human Immune System
21. 2009 Immune and clinical responses in a phase I trial of intranodal naked DNA priming and peptide boost with MART-1 and tyrosinase (MKC1106 MT) in patients with advanced melanoma
22. 2008 Dendritic cell vaccination, together with systemic IL-2/IL-2 mAb in combination, can selectively expand adoptively transferred tumor specific CD8+ T cells in the myeloablative setting.
23. 2008 Combination of Dendritic Cell (DC) Vaccination with CTLA4 Blockade in Patients (pts) with Metastatic Melanoma: A Phase 1 Clinical Trial.
24. 2008 Human melanoma-associated expresion of the endothelial receptor ROBO4 (Magic roundabout hololog 4): Its role in proliferation and tumor-cell survival.
25. 2008 PET Imaging of Cancer Immunotherapy.
26. 2008 Increased Th17 Cells in Melanoma Patients with Autoimmunity Induced by CTLA4 Blocking Antibodies
27. 2008 Insertion of an MHC class I-restricted T cell receptor (TCR) skews the phenotype of genetically engineered human peripheral blood mononuclear cells (PBMC) for adoptive T cell therapy
28. 2008 Phase III, Open-Label, Randomized, Comparative Study of Tremelimumab (CP-675,206) and Chemotherapy (Temozolomide or Dacarbazine) in Patients with Advanced Melanoma
29. 2008 Prognostic role of prior cytokine immunotherapy in outcome of treatment with tremelimumab (CP-675,206) in patients with metastatic melanoma.
30. 2008 Phase I/II study of Imexon (Amplimexon, AMP) plus Dacarbazine (DTIC) in Patients (Pts) with Metastatic Malignant Melanoma.
31. 2008 Improved T Cell Receptor (TCR) Assembly and Stability through Genetic Modification for Melanoma Immunotherapy
32. 2008 Immune-mediated brain tumor regression requires HMGB1 release and subsequent TLR2 activation on tumor infiltrating dendritic cells
33. 2007 MHC Class I-Restricted Tumor Epitope Specific TCR Engineered CD4+ T Cells Function as Helper and Cytolytic Effector Cells in Anti-Tumor Immunity`.
34. 2007 Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study
35. 2007 Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma
36. 2007 Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675,206
37. 2007 Investigation of therapeutic immune-responses to cancer in vivo: tracking lymphocytes with transgenic T-cell-receptor specific to a melanoma antigen by PET imaging
38. 2007 Adoptive Immunotherapy with Melanoma Antigen-specific T cells for CNS Tumors and In Vivo Imaging of T cell Trafficking. The Potent New Anti-Tumor Immunotherapies.
39. 2007 Immunological and Clinical Responses from a Phase I/II Trial Immunizing Melanoma Patients with Autologous Dendritic Cells Transduced with AdVMART1.
40. 2007 In Vivo Imaging of T cell Responses against Self-Antigens in Melanoma
41. 2007 Clearance of monoclonal antibody (mAb) CP-675,206 by therapeutic plasma exchange (TPE) or plasmapheresis.
42. 2006 Modest activity of alpha-fetoprotein (AFP)-based genetic immunotherapy in a spontaneous hepatocarcinogenesis model
43. 2006 Phase II Study of Volociximab (M200), An Anti-Integrin Antibody in Metastatic Melanoma.
44. 2006 Changes in Intratumoral Immune Cell Infiltrates, Foxp3 and Indoleamine 2, 3-dioxygenase (IDO) Expression with the CTLA4 Blocking mAb CP-675,206
45. 2006 Immunological Assays to Differentiate Responders from Non-Responders after CTLA4 Blockade with CP-675,206
46. 2006 A Histone Deacetylase Inhibitor (HDACi) Sensitizes B16 Melanoma to Adoptive Transfer (AT) Immunotherapy.
47. 2006 Adoptive Immunotherapy and In Vivo Imaging of Melanoma Antigen-specific T cells for CNS Tumors.
48. 2006 The objective responses induced by the anti-CTLA4 monoclonal antibody CP-675,206 in patients with melanoma are durable and maintained.
49. 2006 Celecoxib sensitizes human melanoma cells to immune-mediated apoptosis.
50. 2006 A novel ex vivo potency assay for CTLA4 blockade utilized in the development of the CTLA4 blocking Mab CP-675,206.
51. 2006 Antigen-specific T cell responses in patients with melanoma treated with the CTLA4 blocking mAb ticilimumab
52. 2006 Ex vivo blood stimulation assay as a translational research tool in the development of the ticilimumab
53. 2006 Phase 1 Clinical Trials of Ticilimumab: Tumor Responses are Sufficient but not Necessary for Prolonged Survival.
54. 2006 Dose and schedule selection for the anti-CTLA4 monoclonal antibody (mAb) ticilimumab in patients (pts) with metastatic melanoma.
55. 2006 Immunological memory and eradication of glioblastoma in a syngeneic model of recurrent and multifocal disease.
56. 2006 Unpulsed dendritic cells induce anti-tumor immunity to CNS tumors that are dependent upon NK Cells and CD4+ T cells.
57. 2006 Glucocorticoid receptor-dependend FoxP3 transcriptional regulation: Implications for immuno-tolerance and tumor immunotherapy.
58. 2005 Lentiviral Vector Programming of Dendritic Cell Vaccines Results in Improved In Vivo Maintenance, Biodistribution and Immunopotency.
59. 2005 Traf6 siRNA-mediated in vitro sensitization of immune-resistant B16 mouse melanoma cells to TNF-a-induced apoptosis.
60. 2005 Spontaneous AFP-Specific T Cell Responses in Subjects with AFP-positive Hepatocellular Cancer.
61. 2005 Role of Fetal Calf Serum (FCS) in Immune Responses to Dendritic Cell (DC)-Based Immunotherapy in Murine Models
62. 2005 Phase 1 Trial of Monthly Doses of the Human Anti-CTLA4 Monoclonal Antibody CP-675,206 in Patients with Advanced Melanoma.
63. 2005 A Novel Form of Radiation-Induced Immune Suppression.
64. 2004 Phase 1 clinical trial of anti-CTLA-4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies
65. 2004 Characterization of Melanoma Antigen-Specific T Cells in a Long Term Survivor with Metastatic Melanoma with a Stable Peripheral Blood Population of Greater than 5% of MART-1-specific CD8+ T Cells.
66. 2004 Standardization of MHC Tetramer and ELISPOT Assays to Quantitate Antigen-Specific T Cell Expansion after CTLA4 Blockade
67. 2004 A Her2/neu-targeted IL-2 immunocytokine efficiently redirects Her2/neu antigen processing in dendritic cells (DC) resulting in tumor protection
68. 2004 Radiation modulates tumor antigen presentation by dendritic cells.
69. 2004 Regulation of Natural Killer Cells From CD8alpha Knock-Out (CD8KO) Mediating Strong Anti-Tumor Responses.
70. 2004 A Methods Study to Define the Performance Specifications of MHC Tetramer Assays for Immune Monitoring of Tumor Immunotherapy.
71. 2004 T Cell Responses to Alpha-Fetoprotein-Derived Immunodominant Peptide-Pulsed Dendritic Cells in Patients with Hepatocellular Carcinoma
72. 2003 Ionizing Radiation Effects on MHC Class I Antigen Presentation.
73. 2003 A Phase I/II Trial Immunizing Melanoma Patients with Autologous Dendritic Cells Transduced with AdVMART1.
74. 2003 T cell responses to HLA-A*0201 immunodominant peptides derived from alpha fetoprotein in patients with hepatocellular carcinoma.
75. 2003 Broad Tumor Protection Stimulated by Dendritic Cell-Based Immunization in the Absence of CD8+ T Cells
76. 2003 Genetic Immunization with MART-1 Gene-Modified Dendritic Cells.
77. 2002 Gene Therapy of Cancer
78. 2001 Dose and Route of Dendritic Cell-Based Vaccination for Further Human Testing: A Phase I Trial
79. 2000 High level of circulating MART-127-35-specific cells after immunization with MART-127-35-Ppeptide pulsed autologous dendritic cells (DC) in HLA-A*0201+ patients with metastatic melanoma.
80. 2000 CD40 Crosslinking Bypasses the Absolute Requirement for CD4 Cells After Immunization with Melanoma Antigen Gene-Modified Dendritic Cells.
81. 2000 Malignant Melanoma of the Skin
82. 2000 Gene Therapy for Cancer.
83. 2000 Mass Spectrometry Analysis of T Cell Epitopes Derived from Human Alpha Fetoprotein.
84. 1999 Immunological effects of dendritic cell-based immunizations in melanoma
85. 1998 Genetically engineered dendritic cells generate antigen specific immunity in vitro and in vivo.
86. 1998 Generation of anti-tumor immunity using dendritic cells genetically modified to express tumor specific antigen and cytokines
87. 1998 Genetic immunization for cancer. In Gene Therapy of Cancer, Edmund C. Lattime and Stanton L. Gerson Editors.
88. 1998 Identification of a peptide epitope derived from human alpha fetoprotein (AFP) which elicits CTL responses against AFP+ tumors
89. 1998 Interleukin-12-based adenovirus gene therapy of hepatocellular carcinoma.
90. 1997 An E1B attenuated adenovirus selectively inhibits growth of a p53 deficient hepatocellular carcinoma.
91. 1997 Economou. A direct comparison of DC propagated from different progenitor cell populations from one donor.
92. 1997 Efficiency of adenovirus mediated gene delivery into human ovarian cell lines is significantly reduced in presence of ovarian cancer ascites and in three dimensional culture systems
93. 1997 Solitary pituitary lesions in a patient with prior breast cancer
94. 1997 Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support
95. 1997 Treatment of established tumors with gene-modified murine dendritic cells.
96. 1997 Should people with hepatitis C virus infection receive a bone marrow transplant?
97. 1996 M-VAC versus M-CAVI (methotrexate, Carboplatin, vinblastin) in advanced surgically incurable bladder cancer.
98. 1996 High response rate with a CMF-based regimen in advanced and metastatic breast cancer (MBC).
99. 1995 Valor pronastico para suprevivencia de la p53 en pacientes con cancer de vejiga T2-4N0M0 tratados con M-CAVI
100. 1995 4as Jornadas Invernales de Actualizacia n en Oncologia
101. 1995 Transduccion con el gen de la Interleucina 2 y seleccion in vitro de celulas de cencer de cilon murino para ser usadas como vacunas antitumorales en un protocolo de terapia genica
102. 1995 High dose continuous infusion (CI) ifosfamide without hematopoietic support in heavily pretreated breast cancer (BC) and sarcoma (S) patients.
103. 1995 Transduction and selection of murine tumor cells engineered to express the Interleukin 2 (IL-2) and herpes simplex virus thymidine kinase (HSVTK) genes
104. 1995 Prognostic factors for response and survival in patients with invasive bladder cancer treated with neoadjuvant methotrexate, carboplatin, and vinblastine (M-CAVI)
105. 1995 Estudio fase II con Mitomicina C y Mitoxantrone en carcinomas de primario desconocido
106. 1995 Ifosfamida a altas dosis en tumores altamente pretratados
107. 1995 Estudio en fase II de metotrexato, carboplatino y vinblastina (M-CAVI) en el tratamiento neoadyuvante del cáncer de vejiga
108. 1995 V International Symposiun on Biology and Clinica Usefulness of Tumor Markers
109. 1995 p53 overexpression fails to predict survival in a cohort of bladder cancer patients treated with a neoadjuvant carboplatin-based regimen. V International Symposiun on Biology and Clinica Usefulness of Tumor Markers
110. 1995 Corticosteroid treatment for Castleman s disease.
111. 1995 Metastasis osea solitaria como recidiva de un cancer de mama. In M. Martin Editor: Casos clinicos en patologia tumoral maligna.
112. 1995 Carcinoma ductal "in situ" de mama: Diagnostico precoz y tratamiento]. In M. Martin Editor: Casos clinicos en patologia tumoral maligna.
113. 1994 Garcia-Bragado. Plasmablastic lymphoma in a patient seropositive for HIV
114. 1994 Castleman's disease in HIV positive patients and its relation with the occurrence of Kaposi's sarcoma after corticosteroid thearpy.
115. 1994 Preliminary results of a randomized phase II trial comparing M-VAC and M-CAVI for patients with non-metastatic bladder cancer.
116. 1994 Overexpression of p53 and/or HER2/neu predicts a poor disease-free and overall survival in node-negative breast cancer.
117. 1994 Gene Therapy. New Perspectives in the Treatment of Cancer [Terapia Genica: Nuevas perspectivas en el tratamiento del cancer
118. 1994 Linfoma abdominal asociado a SIDA: Hallazgos ecogrificos
119. 1994 1er Curso de Quimioterapia Antineoplasica en Tumores Silidos
120. 1994 Clinicopathological correlation in HIV-related lymphoproliferative diseases
121. 1993 Malignant lymphoproliferative diseases (MLD) in patients seropositive for the human immunodeficiency vitus (HIV).
122. 1991 Hematopoietic growth factors in bone marrow transplantation: Current and future directions.

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.